picibanil and Adenocarcinoma--Mucinous

We evaluated intraperitoneal cytology during surgery as a significant predictor of survival and tried to establish strategies for preventing peritoneal carcinomatosis.. The study included 236 patients with gastric carcinoma macroscopically invading the serosa who underwent intraperitoneal cytological examination during surgery. In the 215 resected patients, the relationship between cytological positivity for cancer cells and various clinicopathologic features was analyzed. Additionally, postoperative survival was assessed in relation to the positivity of intraoperative cytology.. Cancer cells were positive [Cy+] in 78 (33.1%) of 236 patients who underwent cytological examinations. Among 73 patients with peritoneal metastases, 53 patients (72.6%) were Cy+, as were 25 (15.3%) of the 163 patients without peritoneal metastases. Multivariate analysis indicated that peritoneal metastasis (p = 0.0001) and the depth of tumor invasion (p = 0.0069) were significant factors correlated with Cy+. Among patients with curative surgery, the 5-year survival rate of the Cy+ group was 22.2%, which was worse (p = 0.0004) compared with that of the Cy(-) group (60.9%). Among Cy+ patients, the survival rate of the group treated with intraperitoneal administration of mitomycin C (MMC) and OK-432 was better (p = 0.0108) than that of the historical control group.. These results suggest that intraperitoneal cytological examination can be a significant prognostic factor for gastric carcinoma with serosal invasion. In addition, dissemination of cancer cells in the peritoneum may be controlled by intraperitoneal immunochemotherapy with MMC and OK-432.

Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Signet Ring Cell; Combined Modality Therapy; Female; Gastrectomy; Humans; Intraoperative Care; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Peritoneal Cavity; Peritoneal Neoplasms; Picibanil; Postoperative Care; Stomach Neoplasms; Survival Rate

Intraperitoneal and pleural immunotherapy has been used as an effective therapy for malignancy. Recently we treated two patients with peritonitis and pleuritis due to cancer by intraperitoneal and pleural administration of IFN-gamma, OK-432 and antitumor agents. One patient with gastric cancer (stage IIIb) was treated with intraperitoneal administration of IFN-gamma and OK-432 in combination with intraarterial infusion of MMC, ADM, 5-FU and CDDP. Two months later, ascites and pleural fluid diminished. Another patient with ovarian carcinoma (stage IV), was administered IFN-gamma, OK-432 and CDDP into ascites with general medication of CDDP and Epi-ADM. Two months later, her ascites and tumor size decreased. This patient was treated with palaplatin every two months for the ten months and hysterosalpingecctomy and tumorectomy of Douglas pouch were performed at the sixteenth month. The histopathological examination of resection from this patient showed complete necrotic tissue of tumor. Endogenous cytokine therapy with intraperitoneal and pleural administration of IFN-gamma for priming and OK-432 for eliciting in combination with antitumor agents may be effective treatment for malignant peritonitis and pleuritis.

Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Interferon-gamma; Male; Middle Aged; Ovarian Neoplasms; Peritonitis; Picibanil; Pleural Effusion; Pleurisy; Stomach Neoplasms

OK-432 has been injected endoscopically into 4 patients with an unresectable esophageal or gastric cancer. Three months after the initial injection, a remarkable improvement in the symptoms and a reduction of the tumor size was recognized in all 4 patients. This study indicates that an OK-432 injection provides considerable benefits to patients with an advanced esophageal or gastric cancer.

Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Aged, 80 and over; Biological Products; Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal Neoplasms; Esophagoscopy; Gastroscopy; Humans; Injections; Male; Middle Aged; Picibanil; Remission Induction; Stomach Neoplasms

To examine the carcinogenetic and growth inhibitory effects of OK-432, large-bowel carcinoma was induced experimentally in rats by intrarectal injection of N-methyl-N-nitrosourea (MNU), and OK-432 was administered intradermally. Rats were sacrificed after six months and the large intestine was cut into serial sections. Histopathologic examination and analysis of the infiltrating mononuclear cells, using monoclonal antibodies, were performed. The average rate of carcinogenesis per rat was 15.7 +/- 8.5 in the MNU alone group (n = 10) and 8.3 +/- 3.5 in the MNU and OK-432 group (n = 6). The invasion was deeper than the muscularis propria in 16 out of 157 lesions (10.2 percent) in the MNU alone group and in one out of 50 lesions in the MNU + OK-432 group (2.0 percent) (P less than 0.05). When time of appearance of atypical glands or carcinomas were compared in the MNU alone and MNU + OK-432 group, carcinogenesis was found to be delayed in the MNU + OK-432 group. In the investigation of infiltrating mononuclear cells using monoclonal antibodies, there were increases in helper T cells in both the MNU alone and MNU + OK-432 groups, but there was little difference between the two groups. The results of this study suggest that the suppression of experimental carcinogenesis in the large bowel by the concomitant administration of OK-432 with MNU, may be due to the enhanced activation or prolonged activated state of immunocompetent cells, which appear via antigen recognition, by OK-432.

Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Animals; Biological Products; Intestinal Neoplasms; Male; Methylnitrosourea; Picibanil; Rats; Rats, Inbred Strains; Time Factors

A first case of synchronous double cancers in the ovary and kidney is presented. The patient is a 37-year-old woman complaining of an abdominal mass. Histopathological findings showed a mucinous cystadenocarcinoma of the right ovary and a renal cell carcinoma, common type, clear cell subtype of the right kidney. A metastatic renal cell carcinoma was found on the pelvic peritoneum and characteristic renal cancer cells were identified in the ascitic fluid. (. ovarian cancer, stage Ia; renal cancer, stage IV) The patient received postoperative chemotherapy and, after recovery, was discharged in a healthy condition. Her 11-month postoperative evaluation revealed no evidence of disease.

Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Kidney Neoplasms; Middle Aged; Neoplasms, Multiple Primary; Ovarian Neoplasms; Peptichemio; Picibanil; Postoperative Care

One hundred seventeen patients with postoperative ovarian cancer who were treated with whole abdominal irradiation by the open-field technique were analyzed as to the effectiveness of combined therapy with or without OK-432. OK-432, 0.2 to 2.0 (KE) (kev) daily, has been used to prevent bone marrow suppression since 1978 at NIRS. Cumulative five-year survival rates were 63.6% in the OK-432 group (37 patients) and 54.5% in the NON-OK-432 group (34 patients). The complete rates of previously arranged treatment schedules were 81% and 66% in the two groups, respectively, as we originally intended.

Topics: Abdomen; Adenocarcinoma, Mucinous; Biological Products; Combined Modality Therapy; Cystadenocarcinoma; Female; Humans; Ovarian Neoplasms; Picibanil; Radiotherapy Dosage; Radiotherapy, High-Energy

Topics: Abortion, Therapeutic; Adenocarcinoma, Mucinous; Adenoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Ovariectomy; Peptichemio; Picibanil; Pregnancy; Pregnancy Complications, Neoplastic; Prognosis

Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Animals; Antineoplastic Agents, Phytogenic; Dogs; Drug Evaluation, Preclinical; Female; Glycosaminoglycans; Male; Picibanil; Sizofiran; Stomach Neoplasms

Carboquone (CQ) was administered to 20 patients with ovarian cancer as a main drug in the multiple chemotherapy. Picibanil and Futraful (FT-207) were medicated simultaneously. CQ was given 3 mg each, 2 times a week, up to total 30 mg intravenously or intraperitoneally. 1) The effect of CQ was evaluated in 6 cases. The response was good in 2 cases, fair in 3, and poor in 1. In the other 3 cases after surgery long-lasting remission suggested the effectiveness of this drug. 2) When compared with 43 cases of control group(historical control), apparent higher survival rate was observed until 3 years in this group. 3) Side effects were noted in 89% of the patients. In 5 patients CQ treatment was discontinued because of severe complications. These complications were more pronounced when it was administered intraperitoneally or combined with radiation.

Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Azirines; Carbazilquinone; Cystadenocarcinoma; Drug Evaluation; Drug Therapy, Combination; Endometriosis; Female; Humans; Middle Aged; Ovarian Neoplasms; Picibanil; Tegafur